Gestrinone: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 1: | Line 1: | ||
{{Short description|Overview of the drug Gestrinone}} | |||
{{Drugbox | |||
| image = Gestrinone.svg | |||
| image_size = 250px | |||
| image_alt = Chemical structure of Gestrinone | |||
}} | |||
'''Gestrinone''' is a synthetic steroid with both [[progestogen]] and [[antiprogestogen]] properties. It is primarily used in the treatment of [[endometriosis]], a condition where tissue similar to the lining inside the uterus grows outside the uterus, causing pain and potentially leading to infertility. | |||
Gestrinone | ==Pharmacology== | ||
Gestrinone acts as a [[gonadotropin-releasing hormone]] (GnRH) antagonist, which leads to a decrease in the production of [[estrogen]] and [[progesterone]] by the ovaries. This reduction in hormone levels helps to alleviate the symptoms of endometriosis by reducing the growth of endometrial tissue. | |||
== | ===Mechanism of Action=== | ||
Gestrinone binds to [[progesterone receptors]] and [[androgen receptors]], exerting its effects by modulating the activity of these receptors. It also has weak [[androgenic]] activity, which contributes to its therapeutic effects in endometriosis. | |||
Gestrinone is | ==Clinical Use== | ||
Gestrinone is administered orally and is typically prescribed for women who have not responded to other treatments for endometriosis. The usual dosage is 2.5 mg taken twice a week. Treatment duration is generally limited to six months due to potential side effects. | |||
== Side Effects == | ==Side Effects== | ||
Common side effects of gestrinone include weight gain, acne, oily skin, and changes in menstrual bleeding patterns. Due to its androgenic activity, some women may experience [[hirsutism]] or deepening of the voice. | |||
==Contraindications== | |||
Gestrinone is contraindicated in women who are pregnant or breastfeeding, as well as in those with severe liver dysfunction or a history of [[thromboembolic disorders]]. | |||
== Contraindications == | |||
Gestrinone | |||
==Related pages== | |||
* [[Endometriosis]] | * [[Endometriosis]] | ||
* [[ | * [[Progestogen]] | ||
* [[ | * [[Antiprogestogen]] | ||
* [[ | * [[Androgen]] | ||
[[Category:Progestogens]] | |||
[[Category:Antiprogestogens]] | |||
[[Category:Steroids]] | |||
Revision as of 03:47, 13 February 2025
Overview of the drug Gestrinone
| Gestrinone | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Gestrinone is a synthetic steroid with both progestogen and antiprogestogen properties. It is primarily used in the treatment of endometriosis, a condition where tissue similar to the lining inside the uterus grows outside the uterus, causing pain and potentially leading to infertility.
Pharmacology
Gestrinone acts as a gonadotropin-releasing hormone (GnRH) antagonist, which leads to a decrease in the production of estrogen and progesterone by the ovaries. This reduction in hormone levels helps to alleviate the symptoms of endometriosis by reducing the growth of endometrial tissue.
Mechanism of Action
Gestrinone binds to progesterone receptors and androgen receptors, exerting its effects by modulating the activity of these receptors. It also has weak androgenic activity, which contributes to its therapeutic effects in endometriosis.
Clinical Use
Gestrinone is administered orally and is typically prescribed for women who have not responded to other treatments for endometriosis. The usual dosage is 2.5 mg taken twice a week. Treatment duration is generally limited to six months due to potential side effects.
Side Effects
Common side effects of gestrinone include weight gain, acne, oily skin, and changes in menstrual bleeding patterns. Due to its androgenic activity, some women may experience hirsutism or deepening of the voice.
Contraindications
Gestrinone is contraindicated in women who are pregnant or breastfeeding, as well as in those with severe liver dysfunction or a history of thromboembolic disorders.
